Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bomedemstat - Imago BioSciences

Next Previous
Drug Profile

Bomedemstat - Imago BioSciences

Alternative Names: Bomedemstat tosylate - Imago BioSciences; IMG-241 bis-tosylate salt; IMG-7289; LSD1 inhibitor - Imago BioSciences; MK-3543

Latest Information Update: 25 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imago BioSciences
  • Developer Imago BioSciences; University of Hong Kong
  • Class Amides; Amines; Antihaemorrhagics; Antineoplastics; Benzamides; Benzene derivatives; Cyclopropanes; Fluorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Essential thrombocythaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia; Polycythaemia vera
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I/II Small cell lung cancer

Most Recent Events

  • 20 Feb 2026 University of Lincoln plans a phase II trial for Myelofibrosis (Combination therapy) (PO), in November 2026 (NCT07424950)
  • 17 Feb 2026 Merck Sharp & Dohme completes a phase I pharmacokinetic trial in patient with Hepatic impairment in USA (NCT07049939)
  • 19 Jan 2026 Imago BioSciences reinitiates phase I VenBom trial in Acute myeloid leukaemia (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05597306)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top